US biopharmaceutical companies currently have 119 novel medicines in development for the treatment of mental and addictive disorders, according to new industry data.
Products currently in R&D include: 36 for schizophrenia, which affects 2.4 million US adults; 29 for depression – 21 million US adults; 20 for substance/addictive disorders, which cost the nation more than $600 million each year; 15 for attention deficit/hyperactivity disorder (ADHD), affecting one in every 20 US children; and 15 for anxiety disorders, affecting 40 million US adults.
Read more at: http://www.pharmatimes.com/Article/14-05-06/US_biopharma_119_drugs_for_mental_health_disorders_now_in_R_D.aspx